Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.
J Natl Compr Canc Netw
; 15(11): 1429-1437, 2017 11.
Article
em En
| MEDLINE
| ID: mdl-29118234
ABSTRACT
Adoptive T-cell therapy with chimeric antigen receptor T cells (CAR-Ts) has produced impressive clinical responses among patients with B-cell malignancies, and several groups have published positive results using anti-CD19 CAR-Ts for the treatment of B-cell acute lymphoblastic leukemia. Recently, new data from clinical trials have demonstrated the benefits of CAR-T therapy in the non-Hodgkin's lymphoma (NHL) setting. This review describes some of the most recent and promising advances in engineered T-cell therapy, with particular emphasis on the clinical benefits of NHL treatment.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma não Hodgkin
/
Receptores de Antígenos de Linfócitos T
/
Linfócitos T
/
Imunoterapia Adotiva
/
Antígenos CD19
/
Antígenos de Neoplasias
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article